Ayala Pharmaceuticals Inc (ADXS)

[Inoviorulez]

No, the reason for stopping the phase 3 was because there was no near-term value for the single AIM2CERV trial. I read the newsletter and final data for that study was not due until 3 years later. If the only value driver was 3 years later that would have done no good. Results for the cervical were not to be expected until 2022.

Since NEO and HOT had shorter catalysts (closer catalysts) and were next generation they offered more value. Not because of the money.